通过评估基线循环肿瘤DNA生物标志物预测177Lu-PSMA治疗耐药
研究纳入44例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,采集治疗前循环肿瘤DNA(ctDNA)样本,按前列腺特异性抗原应答与否分析基线ctDNA特征。结果显示无应答者基因扩增更常见(75% vs 39.2%,P=0.03),FGFR1扩增(25% vs 0%,P=0.01)和CCNE1扩增(31.2% vs 0%,P=0.001)更常见,CDK12突变更常见(25% vs 3.6%,P=0.05)。作者认为ctDNA检测可能包含预测177Lu-PSMA治疗应答或耐药的特定生物标志物,但需进一步确证研究后才能用于个体化治疗决策。
要点
- 无应答者基因扩增比例高于应答者(75% vs 39.2%,P=0.03)。
- FGFR1扩增在无应答者中更常见(25% vs 0%,P=0.01)。
- CCNE1扩增在无应答者中更常见(31.2% vs 0%,P=0.001)。
核心结论
- ctDNA检测可能包含预测177Lu-PSMA治疗mCRPC患者应答或耐药的特定生物标志物,但需进一步确证研究后才能用于个体化治疗决策。
研究设计与样本
- 采集44例接受177Lu-PSMA治疗的mCRPC患者的治疗前ctDNA样本。
- 按前列腺特异性抗原应答与无应答分组,对比基线ctDNA检测结果。
主要发现
- 无应答者基因扩增比例高于应答者(75% vs 39.2%,P=0.03)。
- FGFR1扩增在无应答者中更常见(25% vs 0%,P=0.01)。
- CCNE1扩增在无应答者中更常见(31.2% vs 0%,P=0.001)。
- CDK12突变在无应答者中更常见(25% vs 3.6%,P=0.05)。
局限性
- 作者指出在临床医生能利用这些发现做出个体化治疗决策之前,需要进一步的确证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA-617 and 177Lu-PSMA I&T (collectively termed 177Lu-PSMA) are currently being used for the treatment of selected metastatic castration-resistant prostate cancer (mCRPC) patients with PSMA PET-positive disease, but biomarkers for these agents remain incompletely understood. Methods: Pretreatment circulating tumor DNA (ctDNA) samples were collected from 44 mCRPC patients receiving 177Lu-PSMA treatment. Prostate-specific antigen responders and nonresponders were assessed relative to the ctDNA findings at baseline. Results: The ctDNA findings indicated that nonresponders were more likely to have gene amplifications than were responders (75% vs. 39.2%, P = 0.03). In particular, amplifications in FGFR1 (25% vs. 0%, P = 0.01) and CCNE1 (31.2% vs. 0%, P = 0.001) were more likely to be present in nonresponders. CDK12 mutations were more likely to be present in nonresponders (25% vs. 3.6%, P = 0.05). Conclusion: Our analyses indicate that ctDNA assays may contain specific biomarkers predictive of response or resistance for 177Lu-PSMA-treated mCRPC patients. Additional confirmatory studies are required before clinicians can use these findings to make personalized treatment decisions.
引用
- Sartor O, Ledet E, Huang M, et al. Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers. J Nucl Med. 2023. PMID: 37770113. doi:10.2967/jnumed.123.266167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。